KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic) (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of EPS (Basic) data on record, last reported at $14.88 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 1737.04% year-over-year to $14.88; the TTM value through Dec 2025 reached $20.4, up 1960.61%, while the annual FY2025 figure was $20.4, 1960.61% up from the prior year.
  • EPS (Basic) reached $14.88 in Q4 2025 per RIGL's latest filing, up from $1.54 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $14.88 in Q4 2025 and bottomed at -$3.09 in Q4 2022.
  • Average EPS (Basic) over 5 years is $0.8, with a median of -$0.08 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 2107.14% in 2022, then skyrocketed 5666.67% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.14 in 2021, then crashed by 2107.14% to -$3.09 in 2022, then soared by 101.62% to $0.05 in 2023, then surged by 1520.0% to $0.81 in 2024, then skyrocketed by 1737.04% to $14.88 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $14.88 in Q4 2025, $1.54 in Q3 2025, and $3.34 in Q2 2025.